SAG
BEAM icon

SageView Advisory Group’s Beam Therapeutics BEAM Stock Holding History

SageView Advisory Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$333 Buy
+12
New +$306 ﹤0.01% 2474

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SageView Advisory Group's BEAM Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Beam Therapeutics (BEAM) in Q4 2025: 12 shares worth $333. The stake represents ﹤0.01% of the portfolio and ranks #2474 among its holdings.

246 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • SageView Advisory Group held 12 shares of Beam Therapeutics worth $333 as of Q4 2025.
  • Beam Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Beam Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2474 holding.
  • 246 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.